Live Breaking News & Updates on Wound Company Profile
Stay updated with breaking news from Wound company profile. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
StockNews.com began coverage on shares of MediWound (NASDAQ:MDWD – Get Rating) in a report released on Saturday morning. The firm issued a sell rating on the biopharmaceutical company’s stock. Several other research firms have also commented on MDWD. Aegis reduced their price target on shares of MediWound from $9.00 to $7.00 and set a buy […] ....
MediWound (NASDAQ:MDWD – Get Rating) had its price objective trimmed by Aegis from $9.00 to $7.00 in a report published on Monday, Benzinga reports. The firm currently has a buy rating on the biopharmaceutical company’s stock. A number of other brokerages also recently issued reports on MDWD. StockNews.com began coverage on shares of MediWound in […] ....
MediWound (NASDAQ:MDWD – Get Rating) posted its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.15) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.15), MarketWatch Earnings reports. MediWound had a negative return on equity of 332.31% and a negative net margin of 44.58%. During the same quarter last year, the […] ....
MediWound Ltd. (NASDAQ:MDWD – Get Rating) – Equities researchers at Oppenheimer issued their Q1 2022 earnings estimates for MediWound in a note issued to investors on Monday, March 7th. Oppenheimer analyst K. Degeeter anticipates that the biopharmaceutical company will earn ($0.09) per share for the quarter. Oppenheimer also issued estimates for MediWound’s Q2 2022 earnings […] ....
StockNews.com started coverage on shares of MediWound (NASDAQ:MDWD – Get Rating) in a research note issued to investors on Wednesday. The firm set a “sell” rating on the biopharmaceutical company’s stock. NASDAQ MDWD opened at $2.41 on Wednesday. The company has a market cap of $65.64 million, a P/E ratio of -6.02 and a beta […] ....